Relay Therapeutics Statistics
Total Valuation
RLAY has a market cap or net worth of $4.19 billion. The enterprise value is $3.31 billion.
| Market Cap | 4.19B |
| Enterprise Value | 3.31B |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RLAY has 217.94 million shares outstanding. The number of shares has increased by 12.39% in one year.
| Current Share Class | 217.94M |
| Shares Outstanding | 217.94M |
| Shares Change (YoY) | +12.39% |
| Shares Change (QoQ) | +12.79% |
| Owned by Insiders (%) | 1.72% |
| Owned by Institutions (%) | 55.40% |
| Float | 154.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 405.35 |
| Forward PS | 435.88 |
| PB Ratio | 4.85 |
| P/TBV Ratio | 4.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 320.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.27, with a Debt / Equity ratio of 0.03.
| Current Ratio | 18.27 |
| Quick Ratio | 17.93 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.77% and return on invested capital (ROIC) is -23.95%.
| Return on Equity (ROE) | -36.77% |
| Return on Assets (ROA) | -22.88% |
| Return on Invested Capital (ROIC) | -23.95% |
| Return on Capital Employed (ROCE) | -33.87% |
| Weighted Average Cost of Capital (WACC) | 13.52% |
| Revenue Per Employee | $53,627 |
| Profits Per Employee | -$1.48M |
| Employee Count | 193 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +446.18% in the last 52 weeks. The beta is 1.70, so RLAY's price volatility has been higher than the market average.
| Beta (5Y) | 1.70 |
| 52-Week Price Change | +446.18% |
| 50-Day Moving Average | 17.57 |
| 200-Day Moving Average | 11.67 |
| Relative Strength Index (RSI) | 54.68 |
| Average Volume (20 Days) | 2,117,061 |
Short Selling Information
The latest short interest is 42.56 million, so 19.53% of the outstanding shares have been sold short.
| Short Interest | 42.56M |
| Short Previous Month | 43.04M |
| Short % of Shares Out | 19.53% |
| Short % of Float | 27.48% |
| Short Ratio (days to cover) | 9.47 |
Income Statement
In the last 12 months, RLAY had revenue of $10.35 million and -$286.04 million in losses. Loss per share was -$1.57.
| Revenue | 10.35M |
| Gross Profit | -249.16M |
| Operating Income | -310.44M |
| Pretax Income | -286.04M |
| Net Income | -286.04M |
| EBITDA | -308.22M |
| EBIT | -310.44M |
| Loss Per Share | -$1.57 |
Balance Sheet
The company has $910.93 million in cash and $30.66 million in debt, with a net cash position of $880.28 million or $4.04 per share.
| Cash & Cash Equivalents | 910.93M |
| Total Debt | 30.66M |
| Net Cash | 880.28M |
| Net Cash Per Share | $4.04 |
| Equity (Book Value) | 890.01M |
| Book Value Per Share | 4.07 |
| Working Capital | 877.28M |
Cash Flow
| Operating Cash Flow | -212.21M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.21M |
| Net Borrowing | n/a |
| Free Cash Flow | -212.21M |
| FCF Per Share | -$0.97 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,999.37% |
| Pretax Margin | -2,763.64% |
| Profit Margin | n/a |
| EBITDA Margin | -2,978.01% |
| EBIT Margin | -2,999.37% |
| FCF Margin | n/a |
Dividends & Yields
RLAY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.39% |
| Shareholder Yield | -12.39% |
| Earnings Yield | -6.82% |
| FCF Yield | -5.06% |
Analyst Forecast
The average price target for RLAY is $26.08, which is 35.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.08 |
| Price Target Difference | 35.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 28.07% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |